BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
10 2019
Historique:
received: 02 01 2019
revised: 22 03 2019
accepted: 07 05 2019
pubmed: 22 5 2019
medline: 10 3 2020
entrez: 22 5 2019
Statut: ppublish

Résumé

BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. Knowledge of the PSV distribution in African descent individuals is poorly understood. We undertook a systematic review of the published literature and publicly available databases reporting BRCA1/2 PSVs also accessed the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) database to identify African or African descent individuals. Using these data, we inferred which of the BRCA PSVs were likely to be of African continental origin. Of the 43,817 BRCA1/2 PSV carriers in the CIMBA database, 469 (1%) were of African descent. Additional African descent individuals were identified in public databases (n = 291) and the literature (n = 601). We identified 164 unique BRCA1 and 173 unique BRCA2 PSVs in individuals of African ancestry. Of these, 83 BRCA1 and 91 BRCA2 PSVs are of likely or possible African origin. We observed numerous differences in the distribution of PSV type and function in African origin versus non-African origin PSVs. Research in populations of African ancestry with BRCA1/2 PSVs is needed to provide the information needed for clinical management and decision-making in African descent individuals worldwide.

Identifiants

pubmed: 31112363
doi: 10.1002/humu.23804
pmc: PMC6764847
mid: NIHMS1031504
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1781-1796

Subventions

Organisme : University of Pennsylvania: National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855; Breast Cancer Research Foundation; Susan G. Komen Foundation for the cure, Basser Research Center for BRCA. UPITT/MWH: Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation
ID : R01-CA083855
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA156732
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA083855
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA116201
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037517
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA112486
Pays : United States
Organisme : NCI NIH HHS
ID : N02CP65504
Pays : United States
Organisme : NCI NIH HHS
ID : 5U54CA156732-07
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192393
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : CIMBA: CIMBA data management and data analysis were supported by Cancer Research - UK grants C12292/A20861, C12292/A11174. ACA is a Cancer Research -UK Senior Cancer Research Fellow. GCT and ABS are NHMRC Research Fellows. iCOGS: European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), National
Pays : International
Organisme : NCI NIH HHS
ID : N02CP11019
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA130065
Pays : United States
Organisme : HRBCP: Hong Kong Sanatorium and Hospital, Dr Ellen Li Charitable Foundation, Kerry Group Kuok Foundation, National Institute of Health1R 03CA130065, and North California Cancer Center
ID : 03CA130065
Pays : International
Organisme : NCI NIH HHS
ID : R25CA112486
Pays : United States
Organisme : University California San Francisco: UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center
Pays : International
Organisme : NCI: Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50, N02-CP-21013-63 and N02-CP-65504 with Westat, Inc, Rockville, MD
ID : N02-CP-21013-63
Pays : International
Organisme : NCI: Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50, N02-CP-21013-63 and N02-CP-65504 with Westat, Inc, Rockville, MD
ID : N02-CP-65504
Pays : International
Organisme : NCI NIH HHS
ID : R01 CA176785
Pays : United States
Organisme : NCI NIH HHS
ID : RC4 CA153828
Pays : United States
Organisme : NCI: Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50, N02-CP-21013-63 and N02-CP-65504 with Westat, Inc, Rockville, MD
ID : NO2-CP-11019-50
Pays : International
Organisme : NCI NIH HHS
ID : R01 CA142996
Pays : United States
Organisme : BMBSA is supported by Cancer Association of South Africa
Pays : International
Organisme : BCFR - all: CA164920 from National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR
Pays : International
Organisme : NCI NIH HHS
ID : RC4CA153828
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA125183
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA168524
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA161032
Pays : United States
Organisme : Beth Israel Deaconess Medical Center is supported by Breast Cancer Research Foundation
Pays : International
Organisme : NCI NIH HHS
ID : U10 CA027469
Pays : United States
Organisme : Fox Chase Cancer Center: University of Kansas Cancer Center and Kansas Bioscience Authority Eminent Scholar Program and by Chancellors Distinguished Chair in Biomedical Sciences Professorship
ID : R0 1CA140323
Pays : International
Organisme : University of Pennsylvania: National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855; Breast Cancer Research Foundation; Susan G. Komen Foundation for the cure, Basser Research Center for BRCA. UPITT/MWH: Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation
ID : R01-CA102776
Pays : International
Organisme : FPGMX: Mutua Madrileña Foundation (FMMA)
ID : FISPI05/2275
Pays : International
Organisme : GEMO: Ligue Nationale Contre le Cancer; the Association "Le cancer du sein, parlons-en!" Award, Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and French National Institute of Cancer (INCa)
Pays : International
Organisme : Cancer Research UK Grants
ID : C1287/A10118
Pays : International
Organisme : NCI NIH HHS
ID : U01 CA116167
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214545
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128978
Pays : United States
Organisme : Mayo Clinic: NIH, NCI Specialized Program of Research Excellence (SPORE), and a grant from the Breast Cancer Research Foundation
ID : CA116201
Pays : International
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Mayo Clinic: NIH, NCI Specialized Program of Research Excellence (SPORE), and a grant from the Breast Cancer Research Foundation
ID : CA176785
Pays : International
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA116167
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA102776
Pays : United States
Organisme : Mayo Clinic: NIH, NCI Specialized Program of Research Excellence (SPORE), and a grant from the Breast Cancer Research Foundation
ID : CA116167
Pays : International
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA207365
Pays : United States
Organisme : University of California Los Angeles: Jonsson Comprehensive Cancer Center Foundation; Breast Cancer Research Foundation
Pays : International
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA149429
Pays : United States
Organisme : GEORGETOWN: Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), Fisher Center for Hereditary Cancer and Clinical Genomics Research, and Swing Fore the Cure
ID : P30-CA051008
Pays : International
Organisme : NCI NIH HHS
ID : U19 CA148065
Pays : United States
Organisme : UKFOCR: Cancer Research UK
Pays : International
Organisme : Mayo Clinic: NIH, NCI Specialized Program of Research Excellence (SPORE), and a grant from the Breast Cancer Research Foundation
ID : CA192393
Pays : International
Organisme : Cancer Research UK Grants
ID : C1287/A11990
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Breast Cancer Res Treat. 2012 Jul;134(2):889-94
pubmed: 22739995
Hum Mol Genet. 2002 Nov 1;11(23):2805-14
pubmed: 12393792
Fam Cancer. 2009;8(1):15-22
pubmed: 18679828
BMC Public Health. 2014 Jul 28;14:759
pubmed: 25070656
Breast Cancer Res Treat. 2016 Aug;159(1):131-8
pubmed: 27469594
Cancer. 2015 Dec 1;121(23):4173-80
pubmed: 26287763
Fam Cancer. 2014 Sep;13(3):437-44
pubmed: 24729269
Science. 1994 Oct 7;266(5182):120-2
pubmed: 7939630
Nat Genet. 1994 Dec;8(4):387-91
pubmed: 7894491
Science. 1994 Oct 7;266(5182):66-71
pubmed: 7545954
EPMA J. 2010 Sep;1(3):397-412
pubmed: 23199084
BMC Med Genet. 2017 Aug 16;18(1):85
pubmed: 28814288
Am J Hum Genet. 1997 May;60(5):1233-6
pubmed: 9150171
Asian Pac J Cancer Prev. 2014;15(3):1067-74
pubmed: 24606420
Hum Mutat. 2008 Jan;29(1):65-73
pubmed: 17694537
Breast Cancer Res. 2016 Nov 11;18(1):112
pubmed: 27836010
Ann Oncol. 2009 Oct;20(10):1653-9
pubmed: 19491284
Breast Cancer Res Treat. 2010 Nov;124(2):573-7
pubmed: 20596889
Clin Genet. 2012 Feb;81(2):179-84
pubmed: 21204799
Springerplus. 2012 Dec;1(1):83
pubmed: 23519070
Infect Agent Cancer. 2017 Feb 14;12:13
pubmed: 28228841
Hum Genet. 1999 Jul-Aug;105(1-2):28-31
pubmed: 10480351
J Public Health Afr. 2018 Jul 06;9(1):663
pubmed: 30079159
J Natl Compr Canc Netw. 2006 Feb;4(2):177-82
pubmed: 16451773
Hum Genet. 2003 Oct;113(5):452-60
pubmed: 12942367
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7
pubmed: 19141781
JAMA. 2005 Oct 19;294(15):1925-33
pubmed: 16234499
Int J Cancer. 2012 Sep 1;131(5):1114-23
pubmed: 22034289
Breast Cancer Res Treat. 2007 Apr;102(2):189-99
pubmed: 17333343
Hum Mutat. 2006 Oct;27(10):1024-9
pubmed: 16941470
Eur J Hum Genet. 2013 Feb;21(2):212-6
pubmed: 22763381
Oncol Lett. 2011 Nov;2(6):1287-1289
pubmed: 22848303
Lancet Oncol. 2006 Mar;7(3):223-9
pubmed: 16510331
JAMA. 2007 Dec 26;298(24):2869-76
pubmed: 18159056
Hum Mutat. 2018 May;39(5):593-620
pubmed: 29446198
Hum Mutat. 1999 Dec;14(6):545
pubmed: 10571958
Cancer. 2009 May 15;115(10):2222-33
pubmed: 19241424
Breast Cancer Res. 2007;9(2):104
pubmed: 17466083
Breast Cancer Res Treat. 2009 Jan;113(2):393-5
pubmed: 18311584
Breast Cancer Res Treat. 2015 Aug;153(1):201-9
pubmed: 26250392
BMC Cancer. 2015 Nov 17;15:912
pubmed: 26577449
J Med Genet. 2005 Mar;42(3):276-81
pubmed: 15744044
Clin Genet. 2014 Jan;85(1):64-7
pubmed: 23458327
Hum Genet. 1998 May;102(5):549-56
pubmed: 9654203
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1794-9
pubmed: 15533909
Am J Hum Genet. 1997 May;60(5):1021-30
pubmed: 9150149
Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30
pubmed: 17218848
Hum Genet. 2000 Aug;107(2):186-91
pubmed: 11030417
Breast Cancer Res Treat. 2011 Jan;125(2):591-6
pubmed: 20838878
Breast Cancer Res Treat. 2015 Jan;149(1):31-9
pubmed: 25428789
J Clin Oncol. 2018 Oct 1;36(28):2820-2825
pubmed: 30130155
Oncogene. 2006 Jan 12;25(2):323-8
pubmed: 16170354
J Natl Med Assoc. 2000 Jan;92(1):29-35
pubmed: 10800284
Cancer. 2003 Jan 1;97(1 Suppl):236-45
pubmed: 12491487
J Hum Genet. 2018 Apr;63(4):447-457
pubmed: 29176636
J Clin Oncol. 2005 Nov 1;23(31):7804-10
pubmed: 16219936
Genet Test. 2008 Sep;12(3):401-7
pubmed: 18752448
Breast Cancer Res. 2004;6(4):R284-90
pubmed: 15217494

Auteurs

Tara M Friebel (TM)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Dana-Farber Cancer Institute, Boston, Massachusetts.

Irene L Andrulis (IL)

Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

Judith Balmaña (J)

High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.

Amie M Blanco (AM)

Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, California.

Fergus J Couch (FJ)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Mary B Daly (MB)

Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Susan M Domchek (SM)

Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Douglas F Easton (DF)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

William D Foulkes (WD)

Departments of Human Genetics and Oncology, Program in Cancer Genetics, McGill University, Montréal, Quebec, Canada.

Patricia A Ganz (PA)

Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Centre, Schools of Medicine and Public Health, UCLA, Los Angeles, California.

Judy Garber (J)

Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, Massachusetts.

Gord Glendon (G)

Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.

Mark H Greene (MH)

Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland.

Peter J Hulick (PJ)

Center for Medical Genetics, NorthShore University HealthSystem, Evanston, Illinois.
The University of Chicago Pritzker School of Medicine, Chicago, Illinois.

Claudine Isaacs (C)

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.

Rachel C Jankowitz (RC)

Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Beth Y Karlan (BY)

Cedars-Sinai Medical Center, Womens Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California.

Judy Kirk (J)

Familial Cancer Service, Weatmead Hospital, Wentworthville, New South Wales, Australia.

Ava Kwong (A)

Cancer Genetics Centre, Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong, China.
Department of Surgery, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Department of Surgery, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong, China.

Annette Lee (A)

The Feinstein Institute for Medical Research, Manhasset, New York.

Fabienne Lesueur (F)

Genetic Epidemiology of Cancer team, Inserm, Paris, France.
Service de Génétique, Institut Curie, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.

Karen H Lu (KH)

Department of Gynecologic Oncology and Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.

Katherine L Nathanson (KL)

Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Susan L Neuhausen (SL)

Department of Population Sciences, Beckman Research Institute of City of Hop, Duarte, California.

Kenneth Offit (K)

Department of Cancer Biology and Genetics, Clinical Genetics Research Lab, Memorial Sloan-Kettering Cancer Center, New York, New York.
Department of Medicine, Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

Edenir I Palmero (EI)

Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil.
Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, São Paulo, Brazil.

Priyanka Sharma (P)

Division of Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, Kansas.

Marc Tischkowitz (M)

Departments of Human Genetics and Oncology, Program in Cancer Genetics, McGill University, Montréal, Quebec, Canada.
Department of Medical Genetics, Addenbrookes Treatment Centre, Addenbrookes Hosptital, University of Cambridge, Cambridge, UK.

Amanda E Toland (AE)

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio.

Nadine Tung (N)

Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Elizabeth J van Rensburg (EJ)

Department of Genetics, University of Pretoria, Arcadia, South Africa.

Ana Vega (A)

Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain.
Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain.
Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.

Jeffrey N Weitzel (JN)

Clinical Cancer Genetics, City of Hope, Duarte, California.

Gemo Study Collaborators (GS)

Service de Génétique, Institut Curie, Paris, France.

Kent F Hoskins (KF)

Department of Medicine, University of Illinois, Chicago, Illinois.

Tara Maga (T)

Department of Medicine, University of Illinois, Chicago, Illinois.

Michael T Parsons (MT)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Lesley McGuffog (L)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

Antonis C Antoniou (AC)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

Georgia Chenevix-Trench (G)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Dezheng Huo (D)

Center for Clinical Cancer Genetics, The University of Chicago, Chicago, Illinois.

Olufunmilayo I Olopade (OI)

Center for Clinical Cancer Genetics, The University of Chicago, Chicago, Illinois.

Timothy R Rebbeck (TR)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Dana-Farber Cancer Institute, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH